CLINICAL TRIALS PROFILE FOR PIPERACILLIN AND TAZOBACTAM
✉ Email this page to a colleague
All Clinical Trials for PIPERACILLIN AND TAZOBACTAM
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00003805 ↗ | Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count | Completed | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 | 1997-11-01 | RATIONALE: Antibiotic therapy may prevent the development of infection in patients with hematologic cancer and the persistent fever caused by a low white blood cell count. It is not yet known which regimen of antibiotics is most effective in preventing infection in these patients. PURPOSE: Randomized phase III trial to study the effectiveness of piperacillin-tazobactam with or without vancomycin in reducing fever in patients who have leukemia, lymphoma, or Hodgkin's disease. |
| NCT00044746 ↗ | Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 | 2000-10-01 | Phase IV Open-Label Foot Infection Study is being conducted to generate comparative Efficacy and Safety data in Diabetic Inpatients. |
| NCT00044759 ↗ | Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 1969-12-31 | To compare the safety and efficacy of piperacillin/tazobactam (4 g/500 mg) administered intravenously every 6 hours to cefepime (2 g) administered intravenously every 8 hours for the empiric treatment of neutropenic fever in patients with a hematologic malignancy or lymphoma. |
| NCT00167999 ↗ | Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 2005-02-01 | To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units | |
| NCT00195286 ↗ | Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections. | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 2004-06-01 | The primary objective is to study the efficacy of piperacillin/tazobactam in patients with complicated urinary tract infections | |
| NCT00195533 ↗ | Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients | Completed | PETHEMA (Program for the Study and Treatment of Haematological Malignances) | 2001-07-01 | The aim of this study is to compare the efficacy and tolerance of piperacillin-tazobactam versus piperacillin-tazobactam plus glycopeptide as initial empiric antibiotic treatment for fever in neutropenic patients. Study of consecutive cohorts(2). First the patients will be included in the monotherapy branch until completing the predicted number of cases. When this happens, the Coordinating Center will communicate it to the participant centers and from then the patients will be included in the combined therapy. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PIPERACILLIN AND TAZOBACTAM
Condition Name
Clinical Trial Locations for PIPERACILLIN AND TAZOBACTAM
Trials by Country
Clinical Trial Progress for PIPERACILLIN AND TAZOBACTAM
Clinical Trial Phase
Clinical Trial Sponsors for PIPERACILLIN AND TAZOBACTAM
Sponsor Name
